Substance-Related Disorders
Conditions
Keywords
Drug Abuse, Drug Addiction, Drug Dependence, Drug Usage, Drug Use Disorders, Substance Abuse, Substance Addiction, Substance Dependence, Substance Use Disorders
Brief summary
This study will examine the effectiveness of a brief intervention in a primary care setting to reduce drug use or abuse compared to enhanced care as usual.
Detailed description
A substantial body of research has established the efficacy and effectiveness of brief interventions (BI) for excessive or hazardous alcohol use in patients seen in medical settings. Dissemination projects of brief interventions for alcohol and drugs have recently been implemented on a widespread scale. This rapid progression of brief intervention for drugs other than alcohol has outstripped its evidence base. The aims of the study as outlined in the grant are: 1. To examine whether BI is effective at improving outcomes (self-reported drug use and attendance in drug abuse treatment) in individuals with a wide range of problem drug use over and above enhanced care as usual. The enhanced control condition will consist of routine screening, patient notification, and referral for treatment. 2. To test whether fidelity to the BI model or lower severity of drug use is associated with better outcomes. 3. To estimate the impact of BI on several public health outcomes that are directly related to the hazardous effects of illicit drug use, including the use of acute health care services, involvement in the criminal justice system, employment, HIV risk behavior, and mortality. 4. To estimate the costs of the intervention, potential cost offsets, and its incremental cost-effectiveness versus enhanced usual care from the payer perspective based on health care service use and drug use frequency.
Interventions
BEHAVIORALBrief intervention using motivational interviewing
One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
Sponsors
National Institute on Drug Abuse (NIDA)
University of Washington
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* at least 18 years old * receive medical care at one of the participating primary care clinics at Harborview Medical Center/University of Washington Medical Center * will maintain care at the clinic for one year * have a phone or easy access to phone, voicemail, or email * used recreational drugs in the last 3 months * used prescription medications not as prescribed in the last 3 months
Exclusion criteria
* participation in any formal substance abuse treatment programs in the last 30 days (excluding 12-step or self-help groups) * terminal illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Use of illicit drugs in the past 30 days | baseline, 3, 6, 9, and 12 months | Use of illicit drugs in the past 30 days will be measured by self-reported days of use in the past 30 days and validated by urine toxicological screen. |
| Enrollment in formal substance abuse treatment | baseline up to 2 years post-intervention | Enrollment in formal substance abuse treatment will be measured as an admission to chemical dependency treatment as recorded in the Washington State TARGET database. |
| Medical, legal, employment, social, and psychiatric outcomes | baseline, 3, 6, 9, and 12 months | Medical, legal, employment, social, and psychiatric outcomes will be measured by composite scores on the Addiction Severity Index (ASI) Lite. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Public health outcomes | baseline up to 2 years post-intervention | Public health outcomes will be measured by administrative data sources (emergency room visits, hospitalizations, hospital days, HIV risk behavior, arrests, and death). |
| Cost of the intervention | baseline up to 2 years post-intervention | Cost of the intervention will be measured using methods previously employed in the COMBINE study. |
| Incremental cost-effectiveness | baseline up to 2 years post-intervention | Incremental cost-effectiveness will be measured from the payer perspective based on health care service use and drug use frequency. |
Countries
United States
Outcome results
None listed